OncoMatch/Clinical Trials/NCT06021626
A Study of CRD3874-SI in People With Solid Tumors
Is NCT06021626 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CRD3874 for sarcoma.
Treatment: CRD3874 — This study will test the safety of a study drug called CRD3874-SI. The researchers will test different doses of CRD3874-SI to find the highest dose that causes few or mild side effects in participants. After the researchers find the highest safe dose of CRD3874-SI, they will test that dose in new groups of participants to help them learn more about the side effects of the study drug and find out whether CRD3874-SI is an effective treatment for for patients with advanced or metastatic malignant solid tumors including sarcoma and Merkel Cell Carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Tumor Agnostic
Performance status
ECOG/KPS 0–1
Prior therapy
Lab requirements
Blood counts
Hemoglobin 9.0 g/dL; Absolute neutrophil count 1,000/mm^3; Platelet count 100,000/mm3
Kidney function
Calculated creatinine clearance (CrCl) 60 mL/min by Cockcroft-Gault formula or CKD-EPI 2021
Liver function
Serum bilirubin 1.2x ULN OR direct bilirubin ULN for participants with total bilirubin level > 1.2x ULN; AST 2.5x ULN OR 5x ULN for participants with liver metastases; ALT 2.5x ULN OR 5x ULN for participants with liver metastases; Albumin 2.5mg/dL.
Cardiac function
Left ventricular ejection fraction (LVEF) > 50%, as measured by echocardiogram (2D-ECHO) or multi-gated acquisition scan (MUGA)
Adequate organ function determined within 14 days of treatment initiation, defined as follows: Hemoglobin 9.0 g/dL; Absolute neutrophil count 1,000/mm^3 (1.0 x 10^9/L); Platelet count 100,000/mm3 (100 x 10^9 /L); Serum bilirubin 1.2x upper limit of normal (ULN) OR direct bilirubin ULN for participants with total bilirubin level > 1.2x ULN; Aspartate aminotransferase (AST) 2.5x ULN OR 5x ULN for participants with liver metastases; Alanine aminotransferase (ALT) 2.5x ULN OR 5x ULN for participants with liver metastases; Albumin 2.5mg/dL. Calculated creatinine clearance (CrCl) 60 mL/min by Cockcroft-Gault formula or CKD-EPI 2021; International Normalized Ratio (INR) or prothrombin time (PT) 1.5x ULN unless participant is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants. Activated partial thromboplastin time (aPTT) 1.5x ULN unless participant is receiving anticoagulant therapy as long as PT and PTT is within therapeutic range of intended use of anticoagulants; Left ventricular ejection fraction (LVEF) > 50%, as measured by echocardiogram (2D-ECHO) or multi-gated acquisition scan (MUGA)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify